قالب وردپرس درنا توس
Home / Business / AbbVie Buyer Allergan is not the right means for the stock

AbbVie Buyer Allergan is not the right means for the stock



In the six years since the Abbvie split from Abbott Laboratories, the company has been heading for a cliff: the end of US patent security for its criminal substance Humira.

Sale of Humira, Treating Rheumatoid Arthritis and a Dozen Other Diseases, accounts for more than half of AbbVie's annual revenue. With the drug losing patent security in the United States in 2023, the company has been running for a short time to find out how to fill that hole hole.


Source link